Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDH1 | O75874 | 12/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.37 |
| ▸ | HTR2C | P28335 | 1/20 | 0.37 |
| ▸ | HTR2B | P41595 | 1/20 | 0.37 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.34 |
| ▸ | DRD2 | P14416 | 1/20 | 0.33 |
| ▸ | DRD1 | P21728 | 1/20 | 0.33 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.33 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.33 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL483331 | 0.79 | HTR2A (0.37) | IDH1HTR2AHTR2CHTR2BADRA1A | |
| SCHEMBL8039039 | 0.79 | GSK3B (0.39) | IDH1HTR2AHTR2CHTR2BADRA1A | |
| SCHEMBL1769307 | 0.77 | GAA (0.41) | IDH1 | |
| SCHEMBL21905591 | 0.76 | IDH1 (0.40) | IDH1 | |
| SCHEMBL8325895 | 0.75 | DRD2 (0.38) | IDH1HTR2AHTR2CHTR2BDRD2 | |
| SCHEMBL18067769 | 0.75 | IDH1 (0.36) | IDH1HTR2AHTR2CHTR2BADRA1A | |
| SCHEMBL18068274 | 0.75 | PDPK1 (0.38) | IDH1HTR2AHTR2CHTR2BADRA1A | |
| SCHEMBL28153638 | 0.75 | IDH1 (0.36) | IDH1HTR2AHTR2CHTR2BADRA1A | |
| SCHEMBL18068310 | 0.72 | GSK3B (0.37) | IDH1ADRA1AADRA2A | |
| SCHEMBL20073751 | 0.72 | IDH1 (0.43) | IDH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10208061-B2 | Tetrahydro[1,8]naphthyridine sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease | LYCERA CORPORATION (US) | 2019-02-19 | — | — | US | disclosed |
| US-20180179224-A1 | Tetrahydro[1,8]naphthyridine Sulfonamide And Related Compounds for Use as Agonists of RORy and the Treatment of Disease | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2018-06-28 | — | — | US | disclosed |
| US-9802958-B2 | Tetrahydro[1,8]naphthyridine sulfonamide and related compounds for use as agonists of RORy and the treatment of disease | LYCERA CORPORATION (US) | 2017-10-31 | — | — | US | disclosed |
| EP-2847198-B1 | TETRAHYDRO[1,8]NAPHTHYRIDINE SULFONAMIDE AND RELATED COMPOUNDS FOR USE AS AGONISTS OF ROR-GAMMA AND THE TREATMENT OF DISEASE | LYCERA CORP (US) | 2016-12-14 | — | — | EP | disclosed |
| US-20160318951-A1 | Tetrahydro[1,8]naphthyridine Sulfonamide And Related Compounds for Use as Agonists of RORy and the Treatment of Disease | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2016-11-03 | — | — | US | disclosed |
| US-9394315-B2 | Tetrahydro[1,8]naphthyridine sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease | LYCERA CORPORATION (US) | 2016-07-19 | — | — | US | disclosed |
| US-20150133437-A1 | Tetrahydro[1,8]naphthyridine Sulfonamide and Related Compounds for Use as Agonists of RORy and the Treatment of Disease | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2015-05-14 | — | — | US | disclosed |
| EP-2847198-A2 | TETRAHYDRO[1,8]NAPHTHYRIDINE SULFONAMIDE AND RELATED COMPOUNDS FOR USE AS AGONISTS OF ROR AND THE TREATMENT OF DISEASE | Lycera Corporation (US) | 2015-03-18 | — | — | EP | disclosed |
| WO-2013169864-A2 | TETRAHYDRO[1,8]NAPHTHYRIDINE SULFONAMIDE AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORƴ AND THE TREATMENT OF DISEASE | LYCERA CORPORATION (US) | 2013-11-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150133437-A1 | Tetrahydro[1,8]naphthyridine Sulfonamide and Related Compounds for Use as Agonists of RORy and the Treatment of Disease | RORC, RORA, RORB | IDH1 1562/4885HTR2A 2333/4885HTR2C 2177/4885 |
| US-20160318951-A1 | Tetrahydro[1,8]naphthyridine Sulfonamide And Related Compounds for Use as Agonists of RORy and the Treatment of Disease | RORA, RORC, RORB | IDH1 1859/4885HTR2A 1723/4885HTR2C 1726/4885 |
| US-20180179224-A1 | Tetrahydro[1,8]naphthyridine Sulfonamide And Related Compounds for Use as Agonists of RORy and the Treatment of Disease | RORA, RORC, RORB | IDH1 1918/4885HTR2A 1133/4885HTR2C 1250/4885 |
| US-10208061-B2 | Tetrahydro[1,8]naphthyridine sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease | RORC, RORA, RORB | IDH1 2339/4885HTR2A 2150/4885HTR2C 1574/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.